These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38170135)

  • 1. Machine learning to identify risk factors associated with the development of ventilated hospital-acquired pneumonia and mortality: implications for antibiotic therapy selection.
    Sophonsri A; Lou M; Ny P; Minejima E; Nieberg P; Wong-Beringer A
    Front Med (Lausanne); 2023; 10():1268488. PubMed ID: 38170135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
    BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inappropriate Empiric Therapy Impacts Complications and Hospital Resource Utilization Differentially Among Different Types of Bacterial Nosocomial Pneumonia: A Cohort Study, United States, 2014-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Zilberberg NWD; Shorr AF
    Crit Care Explor; 2022 Apr; 4(4):e0667. PubMed ID: 35415613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Shorr AF
    Infect Control Hosp Epidemiol; 2022 Mar; 43(3):277-283. PubMed ID: 35322770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
    Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
    Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial.
    Lodise T; Yang J; Puzniak LA; Dillon R; Kollef M
    Infect Dis Ther; 2020 Dec; 9(4):953-966. PubMed ID: 32996064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Descriptive epidemiology of hospitalized patients with bacterial nosocomial pneumonia who experience 30-day readmission in the US, 2014-2019.
    Zilberberg MD; Nathanson BH; Puzniak LA; Zilberberg NWD; Shorr AF
    PLoS One; 2022; 17(12):e0276192. PubMed ID: 36490261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
    Naik J; Puzniak L; Critchlow S; Elsea D; Dillon RJ; Yang J
    Infect Dis Ther; 2021 Jun; 10(2):939-954. PubMed ID: 33837518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.
    Puzniak L; Dillon R; Palmer T; Collings H; Enstone A
    Infect Dis Ther; 2021 Sep; 10(3):1227-1252. PubMed ID: 34278551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study.
    Chang Y; Jeon K; Lee SM; Cho YJ; Kim YS; Chong YP; Hong SB
    J Korean Med Sci; 2021 Oct; 36(41):e251. PubMed ID: 34697926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventilator-associated pneumonia complicating the acute respiratory distress syndrome.
    Iregui MG; Kollef MH
    Semin Respir Crit Care Med; 2001 Jun; 22(3):317-26. PubMed ID: 16088683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P; Kiratisin P; Thamlikitkul V
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?
    Guillamet CV; Vazquez R; Noe J; Micek ST; Kollef MH
    Medicine (Baltimore); 2016 Aug; 95(35):e4708. PubMed ID: 27583907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti-pseudomonal β-lactam: Does "S" equal success in the presence of resistance to other anti-pseudomonal β-lactams?
    Lodise TP; Puzniak LA; Chen LH; Tian Y; Wei R; Im TM; Tartof SY
    Pharmacotherapy; 2021 Aug; 41(8):658-667. PubMed ID: 34097763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial.
    Martin-Loeches I; Shorr AF; Wunderink RG; Kollef MH; Timsit JF; Yu B; Huntington JA; Jensen E; Bruno CJ
    Ann Intensive Care; 2023 Feb; 13(1):8. PubMed ID: 36773112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
    Motowski H; Ilges D; Hampton N; Kollef MH; Micek ST
    Crit Care Explor; 2023 Mar; 5(3):e0867. PubMed ID: 36861046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use.
    Rhee C; Kadri SS; Dekker JP; Danner RL; Chen HC; Fram D; Zhang F; Wang R; Klompas M;
    JAMA Netw Open; 2020 Apr; 3(4):e202899. PubMed ID: 32297949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
    Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
    Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.